NCT01691755View on ClinicalTrials.gov

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Placebo

oral doses once a day for 26 weeks

DRUG

aleglitazar

150 mcg orally once a day for 26 weeks

Trial Locations (34)

11650

Mexico City

16602

Altoona

16684

Tipton

18510

Scranton

20230

Aguascaliente

27408

Greensboro

29651

Greer

30338

Atlanta

32216

Jacksonville

33024

Cooper City

33134

Coral Gables

33472

Boynton Beach

34000

Durango

34080

Durango

34741

Kissimmee

37919

Knoxville

42090

Pachuca

44600

Guadalajara

46123

Avon

60607

Chicago

62250

Cuernavaca

63376

City of Saint Peters

64460

Monterrey

76000

Querétaro

80020

Culiacán

89000

Tampico

90057

Los Angeles

91307

West Hills

91360

Thousand Oaks

91710

Chino

91786

Upland

92701

Santa Ana

97239

Portland

99202

Spokane

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01691755 - A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy | Biotech Hunter | Biotech Hunter